FORA Capital LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 23,895 shares of the biopharmaceutical company's stock, valued at approximately $2,677,000.
A number of other large investors also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at $25,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at $29,000. Colonial Trust Advisors grew its position in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares during the last quarter. Core Alternative Capital grew its position in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares during the last quarter. Finally, IMA Advisory Services Inc. purchased a new position in Gilead Sciences during the 1st quarter worth $39,000. 83.67% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Price Performance
Shares of NASDAQ GILD traded up $0.41 during midday trading on Friday, hitting $112.97. The company had a trading volume of 4,629,720 shares, compared to its average volume of 6,327,395. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $77.74 and a twelve month high of $121.83. The business has a 50-day simple moving average of $113.01 and a two-hundred day simple moving average of $109.63. The firm has a market capitalization of $140.17 billion, a price-to-earnings ratio of 22.50, a price-to-earnings-growth ratio of 0.70 and a beta of 0.33.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter last year, the business earned $2.01 earnings per share. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.
Analyst Ratings Changes
GILD has been the topic of several research reports. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. UBS Group raised their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Finally, Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $115.39.
Read Our Latest Research Report on GILD
Insider Activity at Gilead Sciences
In related news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company's stock, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,371,330 over the last three months. 0.27% of the stock is currently owned by company insiders.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
